Resistance Exercise Training for Muscle Loss in Older Adults With Type 2 Diabetes
Tests strength training exercise in older adults with type 2 diabetes and muscle loss.
Plain-language title generated from the registry record
Registry title: Results of Progressive Resistance Training in Older Type 2 Diabetic Patients With Sarcopenia
Key facts
- Where
- Hanoi, VietnamSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 60 and 80 years old?
Source: NCT06337357, who can take part
Where in Vietnam
- National Geriatric HospitalHanoi, VietnamTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Geriatric Hospital
- Trial code
- NCT06337357
- Record updated
- 22 May 2025
- Original description
A randomized controlled clinical trial that will test how progressive resistance training will impact outcomes of sarcopenia in older patients with type 2 diabetes who have been diagnosed as sarcopenia. The intervention will be 12 weeks in duration with approximately 24 sessions of resistance exercises. Outcome measures will be collected at baseline, 4, 8 weeks and 12 weeks.Read full original descriptionShow less
Evaluating Resistance Training for Sarcopenia in Older Patients With Type 2 Diabetes: Treatment Outcomes
A randomized controlled clinical trial that will test how progressive resistance training will impact outcomes of sarcopenia in older patients with type 2 diabetes who have been diagnosed as sarcopenia. The intervention will be 12 weeks in duration with approximately 24 sessions of resistance exercises. Outcome measures will be collected at baseline, 4, 8 weeks and 12 weeks.
Inclusion: Type 2 diabetic patients diagnosed using American Diabetes Association 2022 criteria; HbA1c ≥ 7.0 and ≤ 8.5%; Sarcopenia diagnosed using criteria from the Asian Working Group for Sarcopenia 2019; Age ≥ 60 and ≤ 80.
Exclusion: Patients are in the acute phase of musculoskeletal disorders: acute gout, progressing low-grade arthritis, acute joint pain due to joint degeneration, sciatic pain, and infectious arthritis; Patients suffer from conditions significantly affecting cognition and mobility: sequelae of stroke (with weakness, limb paralysis), muscular weakness, limb disabilities, severe heart failure, severe cognitive decline, and psychiatric disorders; Patients have been bedridden due to illness for more than 1 month within the past 3 months up to the recruitment time; Patients with cardiovascular diseases: chest pain, uncontrolled blood pressure ≥160/100 mmHg, untreated cardiac arrhythmia, a history of congestive heart failure, severe valvular heart disease, myocarditis or pericarditis, and hypertrophic cardiomyopathy; Renal failure with estimated glomerular function rate (Modification of Diet in Renal Disease equation) < 60 ml/min/m3 or serum creatinine ≥ 130 µmol/l; On treatment with Sodium-glucose cotransporter 2 inhibitors (SGLT2i); Acute diabetic complications.